* Minor estimate revisions * On track to reach 1m paying users in '25e * Maintain fair value range o...
Redeye provides its comment on Mendus’ Q2 2025 report.
Omsättningen sjönk till 6,6 (10,2) meur, varav PremierGaming stod för 5,8%.
* '25e-'27e sales down 1-3% * Aurdel comps keep getting easier * '26e EV/sales of just below 0.
Redeye provides a research update following the Q2 report published by OncoZenge earlier today.
Solteq’s Q2 results fell short of our expectations.
Despite a weaker-than-expected quarter in terms of revenue and profitability, we are raising our sal...
Redeye provides a research update following the Q2 report published by Alzinova earlier today.
Redeye provides its initial take on Acarix’s Q2 report, which showed a year-on-year increase in both...
* Stable financials * Orviglance FDA submission in early September * Neutral share price reaction ex...
* Sales -4% and adj. EBIT -11% vs ABGSCe * DOCS adoption 23% of municipalities * Consensus adj.
Redeye provides its initial take on Navigo’s Q2 2025 report, which came in broadly below our estimat...
* Sales -4% vs. ABGSCe at SEK 55m * EBITDA better than expected (SEK -0.
Redeye comments on Teneo AI’s Q2, showing flat underlying q/q ARR growth.
* Q2 EBIT of SEK 315m, +11% vs. ABGSC and +7% vs. consensus * Announces buyback of bonds of max SEK ...
* Ework enters its eighth market: Germany * Cost-effective action, while moving along existing clien...
Redeye provides its initial take on Surgical Science’s Q2 2025 report, which aligned with its profit...
Egetis has launched Emcitate in Germany. The progress made in the US include advancing the US study ...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with H...
Redeye updates its estimates and valuation following the Q2 2025 report from Cheffelo.
